patients and methods this cross - sectional study was conducted on 143 thalassemic patients with chronic hepatitis c, who were treated with a combination of peg-ifn and rbv regimen. the rs12979860 and rs8099917 polymorphisms were assessed as the most common polymorphisms near the il28b gene by the polymerase chain reaction-restriction fragment length polymorphism (pcr-rflp) method. objectives w...

BACKGROUND Treatment of Chronic Hepatitis C is now well established with conventional interferon or pegylated interferon in combination with ribavirin. Peginterferon Alfa and Ribavirin for 6 to 12 months is currently approved initial therapy, which is expensive. Response of our patients to standard Interferon-alpha-2b and ribavirin for 24 weeks have been studied. The objective of this study was...

background the hepatitis c virus (hcv) infection has been identified as a leading cause of progressive liver diseases worldwide. despite new treatment strategies, pegylated interferon alfa-2a (peg-ifnα-2a), in combination with ribavirin (rbv), still represents the gold standard of therapy for hepatitis c in developing countries. results in this study, a significant association was observed betw...

Hepatitis C virus (HCV) infection is a significant worldwide health care problem. Nearly one-third of all patients infected with human immunodeficiency virus (HIV) are coinfected with HCV. Compared with HIV-monoinfected persons, coinfected individuals experience more rapid progression of fibrosis and higher incidence of cirrhosis and death as a result of liver disease. Treatment for HCV infecti...

BACKGROUND The purpose of this study was to investigate the incidence and demographic/clinical factors of alanine aminotransferase (ALT) abnormalities at the end of treatment (EOT) in chronic hepatitis C (CHC) patients with sustained virologic response (SVR). METHODS AND FINDINGS Seven hundred naïve CHC patients who underwent combination treatment between January 2003 and December 2010 were i...

Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. Pegylated interferon α and ribavirin combination is the mainstay of treatment. Severe pulmonary toxicities are rarely reported. We report here a case of severe form of organizing pneumonia secondary to pegylated interferon α therapy presenting as acute respiratory failure. Patient has near...

Background: Pharmacological therapies of proven efficacy in corona virus disease 2019 are still lacking with no antiviral treatment. Impaired type I interferon activity may be responsible for severe COVID-19 patient. We performed prospective, observational, open-label study to evaluate the and safety a single dose Pegylated IFN-α2b addition Remdesivir moderate cases. Aim: The aim this is assess...

Recently, recombinant DNA methods have been successfully applied to interferon production, making adequate quantities available for both in vitro and in vivo testing. Although interferons are in the class of biologic response modifiers, they do have some direct cytotoxic effects on human tumor cells that can be quantitated in vitro with the colony-forming assay. In the clonogenic assay, RPMI-82...